Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Harbour BioMed Forms Immunotherapy Discovery Collaboration with Moderna

publication date: Nov 11, 2022

Harbour BioMed will use its antibody discovery platform to identify nucleic acid-based oncology immunotherapies for ModernaTX  an RNA company. Moderna will own an exclusive sub-licensable license to exploit a panel of sequences against multiple targets, derived from HBM’s proprietary heavy chain only antibody discovery platform. Moderna will be responsible for all development costs, while Nona Biosciences, an HBM subsidiary, will receive upfront and milestone payments, plus royalties. HBM is headquartered in Boston with discovery operations in Rotterdam and labs in Suzhou. More details....

Stock Symbols: (HK: 02142) (NSDQ: MRNA)

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here